regarded < regarding < regardless

Facettes : Author.f AffPays.f AffOrg.f AffRegion.f AffVille.f

List of bibliographic references

Number of relevant bibliographic references: 28.
[0-20] [0 - 20][0 - 28][20-27][20-40]

Ident.	Authors (with country if any)	Title
000000 (2009)	Susan P. Bruce [États-Unis]	Recent Developments in the Treatment of Rheumatoid Arthritis
000020 (2011)	Taras Gout [Royaume-Uni] ; Andrew J. K. Östör [Royaume-Uni] ; Muhammad K. Nisar [Royaume-Uni]	Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review
000031 (2005)	Shumpei Yokota [Japon] ; Takako Miyamae [Japon] ; Tomoyuki Imagawa [Japon] ; Shigeki Katakura [Japon] ; Rumiko Kurosawa [Japon] ; Masaaki Mori [Japon]	Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis
000049 (2012)	Hubert De Boysson [France] ; Jérome Février [France] ; Amélie Nicolle [France] ; Christophe Auzary [France] ; Loïk Geffray [France]	Tocilizumab in the treatment of the adult-onset Still's disease: current clinical evidence
000076 (2011)	Makoto Hirao [Japon] ; Naomi Yamasaki [Japon] ; Hiroki Oze [Japon] ; Kosuke Ebina [Japon] ; Akihide Nampei [Japon] ; Yoshitaka Kawato [Japon] ; Kenrin Shi [Japon] ; Hideki Yoshikawa [Japon] ; Norihiro Nishimoto [Japon] ; Jun Hashimoto [Japon]	Serum level of oxidative stress marker is dramatically low in patients with rheumatoid arthritis treated with tocilizumab
000089 (2013)	Alfredo Adán [Espagne] ; Marina Mesquida [Espagne] ; Victor Llorenç [Espagne] ; Gerard Espinosa [Espagne] ; Blanca Molins [Espagne] ; Maria V. Hernández [Espagne] ; Laura Pelegrín [Espagne]	Tocilizumab treatment for refractory uveitis-related cystoid macular edema
000150 (2012)	O. Psenak [Autriche] ; A. Studnicka-Benke [Autriche] ; R. Greil [Autriche]	Sicherheit der Immunsuppressiva
000176 (2010)	I. H. Tarner [Allemagne] ; U. Müller-Ladner [Allemagne] ; C. Hamm [Allemagne]	Biologika und kardiovaskuläres Risiko
000233 (2010)	Hiroshi Kato [États-Unis] ; David A. Fox [États-Unis]	Are Th17 Cells an Appropriate New Target in the Treatment of Rheumatoid Arthritis?
000246 (2011)	Bernard Bannwarth [France]	Prise en charge thérapeutique de l’inflammation d’origine rhumatismale
000296 (2012)	Adel Alawadhi [Koweït] ; Khaldoon Alawneh [Jordanie] ; Zeyad Ahmed Alzahrani [Arabie saoudite]	The effect of neutralizing antibodies on the sustainable efficacy of biologic therapies: what’s in it for African and Middle Eastern rheumatologists
000461 (2011)	Alberto Migliore [Italie, Espagne] ; Emanuele Bizzi [Italie] ; Serena Broccoli [Italie] ; Bruno Laganà [Italie]	Indirect comparison of etanercept, infliximab, and adalimumab for psoriatic arthritis: mixed treatment comparison using placebo as common comparator
000515 (2010)	Soomin Yoon [Corée du Sud] ; Yong-Sung Kim [Corée du Sud] ; Hyunbo Shim [Corée du Sud] ; Junho Chung [Corée du Sud]	Current perspectives on therapeutic antibodies
000569 (2012)	L. Nibali [Royaume-Uni] ; S. Fedele [Royaume-Uni] ; F. D Iuto [Royaume-Uni] ; N. Donos [Royaume-Uni]	Interleukin‐6 in oral diseases: a review
000925 (2012)	P. A. Laires [Portugal] ; F. Exposto [Portugal] ; R. Mesquita [Portugal] ; A. P. Martins [Portugal] ; L. Cunha-Miranda [Portugal] ; J. E. Fonseca [Portugal]	Patients’ access to biologics in rheumatoid arthritis: a comparison between Portugal and other European countries
000958 (2009)	Ewa M. Paleolog [Royaume-Uni]	The vasculature in rheumatoid arthritis: cause or consequence?
000A67 (2011)	W. Hermann [Allemagne]	Reisen bei rheumatischen Erkrankungen
000C68 (2013)	Min Ni [République populaire de Chine] ; Wei Wei [République populaire de Chine] ; Yichao Wang [République populaire de Chine] ; Na Zhang [République populaire de Chine] ; Hongmei Ding [République populaire de Chine] ; Chen Shen [République populaire de Chine] ; Fang Zheng [République populaire de Chine]	Serum Levels of Calreticulin in Correlation with Disease Activity in Patients with Rheumatoid Arthritis
000C70 (2010)	J. Askling [Suède]	The risk of malignancies in RA patients treated with biologics
000D34 (2007)	Cristiano Alessandri [Italie] ; Rossana Scrivo [Italie] ; Francesca Romana Spinelli [Italie] ; Fulvia Ceccarelli [Italie] ; Leonardo Magrini [Italie] ; Roberta Priori [Italie] ; Guido Valesini [Italie]	Autoantibody Production in Anti‐TNF‐α‐Treated Patients
000E21 (2010)	D. Meyer-Olson [Allemagne] ; K. Hoeper [Allemagne] ; R. E. Schmidt [Allemagne]	Infektionskomplikationen unter Biologika-Therapie bei Patienten mit rheumatoider Arthritis

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Istex/Curation

HfdIndexSelect -h $EXPLOR_AREA/Data/Istex/Curation/AbsEn.i -k "regarding" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Istex/Curation/AbsEn.i  \
                -Sk "regarding" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Istex
   |étape=   Curation
   |type=    indexItem
   |index=    AbsEn.i
   |clé=    regarding
}}

---

This area was generated with Dilib version V0.6.34. Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021